ストックスクリーナーアプリを入手
1.26
1.59%
-0.00
前日終値:
$1.26
開ける：
$1.27
24時間の取引高:
63,646
Relative Volume:
0.90
時価総額：
$6.75M
収益：
-
当期純損益:
$-16.63M
株価収益率:
-2.1356
EPS:
-0.59
ネットキャッシュフロー:
$-21.84M
1週間 パフォーマンス:
+9.73%
1か月 パフォーマンス:
-43.38%
6か月 パフォーマンス:
-86.67%
1年 パフォーマンス:
-62.39%
1日の値動き範囲:
$1.21
$1.29
1週間の範囲:
$1.06
$1.30
52週間の値動き範囲:
$1.05
$11.89
Brainstorm Cell Therapeutics Inc Stock (BCLI) Company Profile
名前
Brainstorm Cell Therapeutics Inc
セクター
電話
201-488-0460
住所
1325 AVENUE OF AMERICAS, NEW YORK, NY
BCLI を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| BCLI | 1.24 | 6.75M | 0 | -16.63M | -21.84M | -0.59 |
| VRTX | 449.44 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.00 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 596.25 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.03 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.90 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Brainstorm Cell Therapeutics Inc Stock (BCLI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-02-04 | アップグレード | Maxim Group | Hold → Buy |
| 2020-11-17 | ダウングレード | Maxim Group | Buy → Hold |
| 2016-12-19 | 繰り返されました | Maxim Group | Buy |
| 2015-12-22 | 繰り返されました | Maxim Group | Buy |
Brainstorm Cell Therapeutics Inc (BCLI) 最新ニュース
Stem Cell Therapy Market to Reach $19.1 Billion by 2031 | Advanced - openPR
Brainstorm Cell Therapeutics Inc. (BCLI) Quarterly 10-Q Report - Quartz
ARMISTICE CAPITAL, LLC Expands Stake in Brainstorm Cell Therapeu - GuruFocus.com
BrainStorm Cell Reports $2.7M Loss, Plans Phase 3b ALS Trial Despite Low Cash | BCLI Stock News - StockTitan
75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight - The Malaysian Reserve
BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing - PR Newswire
Amyotrophic Lateral Sclerosis Market Opportunities, - openPR
BrainStorm Teams with Pluri for Key NurOwn ALS Trial Manufacturing Partnership | BCLI Stock News - StockTitan
Amyotrophic Lateral Sclerosis Treatment Market to Grow by USD 663.7 Million from 2024-2028, as Rising Incidence Drives Demand with AI Redefining Market LandscapeTechnavio - The Malaysian Reserve
BrainStorm regains Nasdaq compliance with bid price rule By Investing.com - Investing.com South Africa
BrainStorm regains Nasdaq compliance with bid price rule - Investing.com India
BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - PR Newswire
Neuromuscular Disease Therapeutics Market Statistical - openPR
BrainStorm Cell Therapeutics Presented Positive Survival Data from NurOwn® Expanded Access Program at 2024 Annual NEALS Meeting - PR Newswire
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Short Interest Update - MarketBeat
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Shares Cross Above 200-Day Moving AverageShould You Sell? - MarketBeat
Amyotrophic Lateral Sclerosis (ALS) Market: Detailed Analysis - openPR
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Brainstorm Cell Therapeutics Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the FirmBCLI - AsiaOne
Stem Cell Therapy Market Projected to Reach $831.9 Million By 2032 - 대구포스트
Short Interest in Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Declines By 91.1% - MarketBeat
Autologous Stem Cell and Non-Stem Cell Based Therapies Industry Report By Type, Application and Geography - Elektrotransports.lv
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated at StockNews.com - MarketBeat
BCLIBrainstorm Cell Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
BrainStorm Cell Therapeutics to Provide Corporate Update on Phase 3b NurOwn® Trial at the 2024 Maxim Healthcare Virtual Summit - StockTitan
Gene and Cell Therapies for CNS Disorders Market to Experience - openPR
Brainstorm cell therapeutics CEO acquires $11,308 in stock By Investing.com - Investing.com Canada
Brainstorm cell therapeutics CEO acquires $11,308 in stock - Investing.com
Brainstorm Therapeutics Advances NurOwn® Phase 3b Trials - TipRanks
Brainstorm Cell Therapeutics, Inc. (BCLI) requires closer examination - US Post News
5 Best Stem Cell Companies to Invest In (November 2024) - Securities.io
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Research Coverage Started at StockNews.com - Defense World
Market Momentum: Brainstorm Cell Therapeutics, Inc. (BCLI) Registers a -12.57 Decrease, Closing at 0.22 - The Dwinnex
Brainstorm Cell Therapeutics, Inc. (BCLI) Stock: A Year of Market Fluctuations - The InvestChronicle
The Potential Rise in the Price of Brainstorm Cell Therapeutics, Inc. (BCLI) following insiders activity - Knox Daily
Cell Therapy Technologies Market Size, Product Trends, Key Drivers, Share Analysis And Forecast To 2033 - WhaTech
Brainstorm Cell Therapeutics Stock Scheduled to Reverse Split on Tuesday, October 1st (NASDAQ:BCLI) - Defense World
Cell Theraputics Industry Analysis by Regions, Types and Application - Elektrotransports.lv
BrainStorm announces reverse stock split - Investing.com
Stem Cell Therapy Market Growth, Size, Research Report and Forecast (2024-2034) - 대구포스트
BrainStorm Cell Therapeutics Announces Presentations on NurOwn® at 2024 Annual NEALS Meeting - PR Newswire
Global Stem Cell Therapy Market Set to Reach $ 831.9 Million by 2032 with a 17.2% CAGR GrowthGlobal Stem Cell Therapy Market Set to Reach $ 831.9 Million by 2032 with a 17.2% CAGR Growth - 대구포스트
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Now Covered by Analysts at StockNews.com - Defense World
Cell Theraputics Market 2024-2032 Analysis - Economica
Balance Sheet Insights: Brainstorm Cell Therapeutics, Inc. (BCLI)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
BCLI’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
SEC Form S-3 filed by Brainstorm Cell Therapeutics Inc. - Quantisnow
Brainstorm Cell Therapeutics expands stock incentive plans - Investing.com India
Brainstorm Cell Therapeutics expands stock incentive plans By Investing.com - Investing.com Canada
Brainstorm Cell Therapeutics Enacts Key Corporate Changes - TipRanks
Brainstorm Cell Therapeutics Inc (BCLI) 財務データ
収益
当期純利益
現金流量
EPS
Brainstorm Cell Therapeutics Inc (BCLI) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Lebovits Chaim | President & CEO |
Sep 30 '24 |
Buy |
0.23 |
22,000 |
5,016 |
1,186,865 |
| Dagher Ibrahim B. | Chief Medical Officer |
Jul 19 '24 |
Sale |
0.35 |
63,000 |
22,069 |
0 |
1.80%
0.42%
大文字化:
|
ボリューム (24 時間):